[Anemia and cardiovascular risk in the chronic kidney disease population--which hemoglobin target should be reached?].
Anemia is frequent when chronic kidney disease develops. Its correction by the use of erythropoietin improves the quality of life, and exercise tolerance, and decreases the cardiovascular risk. However, this later risk is not further decreased or even is increased when the hemoglobin target is set above 13 g/dl as compared to the recommended hemoglobin level between 11 and 12 g/dl. This last target therefor gives the best cost-beneficial effect ratio in the chronic kidney disease population. This target must be the new one.